News

The company has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) based on the data from the phase 3 Sirround clinical development

The approvals for the new indications, tumor necrosis factor-receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) and familial Mediterranean fever (FMF), were based on clinical

SD-809 is an investigational, oral, small-molecule inhibitor of vesicular monoamine 2 transporter, or VMAT2, that is being developed to treat chorea associated with Huntington disease. The positive data

The drug, dubbed Invokamet XR, is a combination of canagliflozin, a sodium glucose cotransporter 2 inhibitor found in Janssen’s Invokana, and an XR formulation of metformin, a commonly

Specifically, Affilogic and Takeda, through its research center in San Diego, California, will leverage their respective competencies to validate and optimize Nanofitins® that enable Takeda to deliver biotherapeutic

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune,

The selected compounds come from a library of small molecules, discovered as part of Turing's research efforts in toxoplasmosis, with significantly improved potency and selectivity over current treatments

The announcement was made at an event in San Francisco, US. The money comes from the Chan Zuckerberg Initiative the couple has started last year for advancing human

Under the five-year, multi-target research partnership, the companies will develop several clinical candidates for the treatment of chronic kidney disease in diabetes patients. Both parties will contribute novel